BioCentury
ARTICLE | Financial News

Cephalon beats Street

August 3, 2005 12:49 AM UTC

CEPH posted second quarter EPS of $0.69, beating by $0.10 the Street's $0.59 estimate and up 53% from $0.45 in the second quarter of 2004. CEPH's EPS excludes charges of $290.1 million related to the company's acquisition of Salmedix and its deal with Alkermes (ALKS) to commercialize Vivitrex naltrexone.

Quarterly sales were up 16% to $272.6 million from $235 million during the same period last year. Sales of narcolepsy and sleep disorder drug Provigil increased 26% to $129.9 million from $102.8 million in the second quarter of 2004. Sales of Actiq fentanyl for breakthrough cancer pain rose 7% to $91.8 million from $85.6 million, and sales of epilepsy drug Gabitril tiagabine decreased 36% to $15.7 million from $24.7 million. ...